Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals, sold 365 shares of common stock to cover tax obligations related to restricted stock units.

Summary

• Mark Jeffrey DeLong, the Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 365 shares of the company's common stock on January 29, 2025.
• The sale was executed at a price of $29.5236 per share.
• This transaction was to cover tax withholding obligations related to restricted stock units that vested on January 28, 2025.
• Following the transaction, Mr. DeLong directly owns 84,308 shares of Apellis Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale of 365 shares is relatively small compared to the total holdings of the executive, which is typical for tax-related sales.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally not considered a significant event.

Key Dates

Keywords

Apellis Pharmaceuticals, insider trading, stock sale, Form 4, executive compensation, restricted stock units, tax withholding